Department of Physiology, Yong Loo Lin School of Medicine (Z.Y.H., J.-W.W., D.Y., M.C.L., Y.P.W., T.W.S.), National University of Singapore.
Key Laboratory of Medical Electrophysiology of Ministry of Education, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, China (G.L.).
Circulation. 2018 Oct 2;138(14):1431-1445. doi: 10.1161/CIRCULATIONAHA.117.031231.
L-type Ca1.2 channels play crucial roles in the regulation of blood pressure. Galectin-1 (Gal-1) has been reported to bind to the I-II loop of Ca1.2 channels to reduce their current density. However, the mechanistic understanding for the downregulation of Ca1.2 channels by Gal-1 and whether Gal-1 plays a direct role in blood pressure regulation remain unclear.
In vitro experiments involving coimmunoprecipitation, Western blot, patch-clamp recordings, immunohistochemistry, and pressure myography were used to evaluate the molecular mechanisms by which Gal-1 downregulates Ca1.2 channel in transfected, human embryonic kidney 293 cells, smooth muscle cells, arteries from Lgasl1 mice, rat, and human patients. In vivo experiments involving the delivery of Tat-e9c peptide and AAV5-Gal-1 into rats were performed to investigate the effect of targeting Ca1.2-Gal-1 interaction on blood pressure monitored by tail-cuff or telemetry methods.
Our study reveals that Gal-1 is a key regulator for proteasomal degradation of Ca1.2 channels. Gal-1 competed allosterically with the Caβ subunit for binding to the I-II loop of the Ca1.2 channel. This competitive disruption of Caβ binding led to Ca1.2 degradation by exposing the channels to polyubiquitination. It is notable that we demonstrated that the inverse relationship of reduced Gal-1 and increased Ca1.2 protein levels in arteries was associated with hypertension in hypertensive rats and patients, and Gal-1 deficiency induces higher blood pressure in mice because of the upregulated Ca1.2 protein level in arteries. To directly regulate blood pressure by targeting the Ca1.2-Gal-1 interaction, we administered Tat-e9c, a peptide that competed for binding of Gal-1 by a miniosmotic pump, and this specific disruption of Ca1.2-Gal-1 coupling increased smooth muscle Ca1.2 currents, induced larger arterial contraction, and caused hypertension in rats. In contrasting experiments, overexpression of Gal-1 in smooth muscle by a single bolus of AAV5-Gal-1 significantly reduced blood pressure in spontaneously hypertensive rats.
We have defined molecularly that Gal-1 promotes Ca1.2 degradation by replacing Caβ and thereby exposing specific lysines for polyubiquitination and by masking I-II loop endoplasmic reticulum export signals. This mechanistic understanding provided the basis for targeting Ca1.2-Gal-1 interaction to demonstrate clearly the modulatory role that Gal-1 plays in regulating blood pressure, and offering a potential approach for therapeutic management of hypertension.
L 型钙通道 1.2(Ca1.2)在血压调节中起着关键作用。半乳糖凝集素 1(Gal-1)已被报道与 Ca1.2 通道的 I-II 环结合,从而降低其电流密度。然而,Gal-1 下调 Ca1.2 通道的机制以及 Gal-1 是否在血压调节中发挥直接作用仍不清楚。
通过共免疫沉淀、Western blot、膜片钳记录、免疫组织化学和压力肌动图等体外实验,评估 Gal-1 下调转染的人胚肾 293 细胞、平滑肌细胞、Lgasl1 小鼠、大鼠和人类患者动脉中 Ca1.2 通道的分子机制。通过向大鼠体内递送 Tat-e9c 肽和 AAV5-Gal-1,进行体内实验,以研究靶向 Ca1.2-Gal-1 相互作用对尾套或遥测方法监测的血压的影响。
我们的研究表明,Gal-1 是 Ca1.2 通道蛋白体降解的关键调节因子。Gal-1 与 Caβ 亚基竞争结合 Ca1.2 通道的 I-II 环。这种 Caβ 结合的竞争性破坏导致通道暴露于多泛素化,从而导致 Ca1.2 降解。值得注意的是,我们证明了在高血压大鼠和患者中,动脉中 Gal-1 减少和 Ca1.2 蛋白水平增加的负相关与高血压有关,而 Gal-1 缺乏会导致小鼠血压升高,因为动脉中 Ca1.2 蛋白水平升高。为了通过靶向 Ca1.2-Gal-1 相互作用直接调节血压,我们通过微量渗透泵给予 Tat-e9c 肽,这是一种与 Gal-1 竞争结合的肽,这种特定的 Ca1.2-Gal-1 偶联破坏增加了平滑肌 Ca1.2 电流,引起动脉收缩更大,并导致大鼠高血压。在对比实验中,通过单次 AAV5-Gal-1 注射在平滑肌中过表达 Gal-1,显著降低自发性高血压大鼠的血压。
我们从分子上定义了 Gal-1 通过取代 Caβ 并暴露特定的多泛素化赖氨酸和掩盖 I-II 环内质网出口信号来促进 Ca1.2 降解。这种机制理解为靶向 Ca1.2-Gal-1 相互作用提供了基础,清楚地表明了 Gal-1 在调节血压中的调节作用,并为高血压的治疗管理提供了一种潜在的方法。